Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tharimmune, Inc. - Common Stock (NQ: THAR )

0.3274 +0.0014 (+0.43%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 587,225
Open 0.3286
Bid (Size) 0.3250 (17)
Ask (Size) 0.3292 (52)
Prev. Close 0.3260
Today's Range 0.3249 - 0.3400
52wk Range 0.1434 - 4.790
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Tharimmune (THAR) Shares Are Moving
Tharimmune shares are trading lower by 16.4% during Wednesday's session. The company announced a 1-for-15 reverse stock split. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga

Performance

YTD
-35.16%
-35.16%
1 Month
-11.61%
-11.61%
3 Month
-12.60%
-12.60%
6 Month
-89.16%
-89.16%
1 Year
+48.75%
+48.75%

More News

Read More
Tharimmune Announces 1-for-15 Reverse Stock Split
Via ACCESSWIRE
Tharimmune, Inc. (NASDAQ: THAR) Featured in Coverage of the EF Hutton Annual Global Conference
Via Investor Brand Network
THAR Stock Earnings: Tharimmune Reported Results for Q4 2023
Via InvestorPlace
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
Via ACCESSWIRE
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
Via ACCESSWIRE
Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
Via ACCESSWIRE
Tharimmune To Participate in Two Upcoming Investor Conferences in May
Via ACCESSWIRE
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
Via ACCESSWIRE
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Via ACCESSWIRE
Tharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Perspective Therapeutics And 3 Other Stocks Under $1 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
Via ACCESSWIRE
Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Tharimmune, Inc. Announces Closing of $11 Million Public Offering
Via ACCESSWIRE
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
Via Newsfile
BioMedNewsBreaks – Tharimmune Inc. (NASDAQ: THAR) Announces Pricing of $10M Public Offering
Via Investor Brand Network
Crude Oil Surges 2%; Tharimmune Shares Plummet
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.